Exosome Diagnostics and Therapeutics Market Size to grow by USD 687.63 million between 2024-2028
According to a research report “ Exosome Diagnostics and Therapeutics Market” by Application (Diagnostic, Therapeutic) End-user (Research and academic institutes, Pharmaceutical and biotechnology companies, Commercial) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 687.63 million, at a CAGR of 23.36% during the forecast period. The burgeoning research landscape of exosomes in healthcare is fueling the expansion of the Exosome Diagnostics and Therapeutics Market. In the domain of cardiovascular diseases (CVDs), exosomes have emerged as a significant area of investigation, offering substantial value and potential. Notable research institutions, such as Shanghai Jiao Tong University and Nanjing Medical University, are spearheading advancements in exosome therapy for CVDs. Additionally, numerous research and academic institutions are dedicated to the development of novel therapeutic methods utilizing exosomes. For instance, Beni-Suef University in Egypt is exploring the impact of microvesicles and exosome therapy on beta-cell mass in type I diabetes, while Fujian Medical University in China is focusing on MSC-derived exosomes for the treatment of multiple organ dysfunction.
Browse market data tables, figures, and in-depth TOC on “Exosome Diagnostics and Therapeutics Market” by Application (Diagnostic, Therapeutic) End-user (Research and academic institutes, Pharmaceutical and biotechnology companies, Commercial) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Application, the Diagnostic segment is projected to dominate the market size in 2024
In the dynamic landscape of life sciences, academic institutions play a pivotal role as hubs for groundbreaking research and innovation. These institutions, dedicated to both education and research, foster knowledge-driven growth through collaborative partnerships with industries and regulatory authorities. In the realm of exosome diagnostics and therapeutics, numerous US-based companies have forged strategic alliances with esteemed academic institutions to advance research and development. Notable research institutions, such as Karolinska Institutet and Fujian Medical University, are at the forefront of this field. Karolinska Institutet is pioneering the application of exosomes in the treatment of lung diseases and cancer, while Fujian Medical University is investigating mesenchymal stem cell (MSC)-derived exosomes for managing multiple organ dysfunction syndrome following surgical repair of acute Type A aortic dissection. These collaborative efforts underscore the significance of academic institutions in driving the future success of exosome-based therapies in clinical practice.
By End-user, Research and academic institutes segment is expected to hold the largest market size for the year 2024
In the realm of Exosome Diagnostics and Therapeutics, the diagnostic market segment dominated with a significant market share in 2023. Early and precise diagnosis is paramount for patients with malignancies or precancerous lesions, as it significantly reduces mortality rates and enhances the chances of recovery. Exosomes play a pivotal role in various physiological and pathological processes, including immunological responses, cancer, cardiovascular disease, and abnormal pregnancies. The implementation of non-invasive liquid biopsy in clinical practice is crucial for reducing the reliance on invasive procedures and improving medical interventions with heightened accuracy. Tumor-derived exosomes (TDEs) are instrumental in the development of metastatic niches, immune evasion, and tumor growth, making them valuable tools for cancer diagnosis, prognosis, and treatment planning.
North America is forecasted to hold the largest market size by region in 2024
The North American market for exosome diagnostics and therapeutics is experiencing substantial growth due to the rising prevalence of chronic and infectious diseases, particularly cancer. According to the Centers for Disease Control and Prevention (CDC), the number of new cancer cases in the US increased by 24% among men to over 1 million cases between 2010 and 2021. This escalating disease burden has fueled an increased demand for research activities aimed at developing new drugs, thereby driving the need for advanced research tools such as exosome research products. Additionally, factors such as an aging population, high expenditure on cancer screening, and the growing number of biotechnology and pharmaceutical companies investing in cancer treatment research are further propelling market expansion in North America.
The Exosome Diagnostics and Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Exosome diagnostics and therapeutics have emerged as a promising area of research in the biomedical field, with potential applications in various diseases including cancer, neurological disorders, and infectious diseases. The University of Pittsburgh and Aethlon Medical are at the forefront of this research, developing innovative technologies for exosome isolation and analysis. In the field of cancer, exosomes have been identified as potential biomarkers for early diagnosis and prognosis of lung cancer, liver cancer, prostate cancer, breast cancer, and others. Exosomes contain various biomolecules such as nucleic acids, metabolites, proteins, and lipids, which can provide valuable information about the disease status and progression. Moreover, exosomes can be used as therapeutic agents for cancer, neurodegenerative diseases like Parkinson's and Alzheimer's, chronic heart failure, cardiovascular dysfunction, autoimmune diseases, and infectious diseases. Exosomes can deliver immune modulators, chemotherapeutic agents, antisense oligonucleotides, short interfering ribonucleic acid, and other therapeutic molecules to target cells, enhancing their therapeutic efficacy. Pharmaceutical companies are also investing in exosome-based drug development for molecular diagnosis and treatment of various chronic diseases. Liquid biopsy using exosomes is a non-invasive and cost-effective alternative to traditional diagnostic methods, making it a promising area of research for viral pathogenicity and immune responses. Overall, the exosome diagnostics and therapeutics market hold significant potential for advancing the field of personalized medicine and improving patient outcomes.
Market Research Overview
The Exosome Diagnostics and Therapeutics Market is a rapidly growing sector in the healthcare industry, particularly in the field of cancer screening, neurodegenerative diseases, and chronic conditions. Exosomes, small extracellular vesicles, contain various biomolecules such as nucleic acids, proteins, metabolites, and lipids, making them ideal biomarkers for molecular diagnosis. Government associations and the VA Healthcare system are investing in exosome research for cancer screening and diagnostics. The geriatric population presents a significant opportunity for exosome-based diagnostics due to the prevalence of chronic diseases. However, stringent regulations and a lack of awareness pose challenges to market growth. Key players in the market include Exosome Diagnostics, University of Pittsburgh, Aethlon Medical, and Pharmaceutical companies for drug development. Isolation kits and instruments are essential tools for exosome research and diagnostics. Liquid biopsy using exosomes is gaining popularity in cancer research for lung, liver, prostate, breast, Parkinson's disease, Alzheimer's disease, chronic heart failure, cardiovascular dysfunction, and autoimmune diseases. Exosomes also have therapeutic potential in the form of immune modulators, chemotherapeutic agents, antisense oligonucleotides, and short interfering RNA. The market is segmented into General Services, Life Science Research, and Diagnostic Procedures. The market in LAMEA is expected to grow significantly due to increasing research activities and government initiatives. Exosomes play a crucial role in cancer progression, central nervous system diseases, cardiovascular diseases, pregnancy, viral pathogenicity, and immune responses. The future of exosome diagnostics and therapeutics holds immense potential for improving patient outcomes and advancing medical research.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
